Dopaminergic diseases. Mechanisms of production and therapeutic options
Abstract
Introduction: Dopamine is a neurotransmitter involved in the regulation of attention, motivation, reward processing and motor control. It is produced in several areas of the brain, such as the substantia nigra and ventral tegmental area, and acts on dopamine receptors in regions such as the prefrontal cortex, striatum and limbic system.
Objective: To present the current status of the involvement of the dopaminergic system in the production of dissimilar diseases such as restless legs syndrome, Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.
Method: A bibliographic search was carried out in the databases Pubmed, Elsevier, SciELO and Lilacs with the descriptors: dopamine, Parkinson's disease, attention deficit hyperactivity disorder (ADHD), schizophrenia and addictions. In the end, 23 articles were selected, cited and referenced in the work.
Development: Although it is known for its relationship with Parkinson's disease, it is a neurotransmitter involved in higher pathways of the central nervous system and its mechanism of action is through receptors for five types of G proteins. Its deficiency in dopaminergic neurons causes symptoms characteristic of the diseases described in the study.
Conclusions: Involvement of dopaminergic pathways is common in diseases such as Parkinson's disease, restless legs syndrome, schizophrenia, and attention deficit hyperactivity disorder.
Keywords: dopamine, attention deficit disorder, schizophrenia, Parkinson's diseaseDownloads
References
Channer B, Matt SM, Nickoloff-Bybel EA, Pappa V, Agarwal Y, Wickman J, et al. Dopamine, Immunity, and Disease. Pharmacol Rev. 2023 [citado 23/07/2024];75(1):62-158. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC9832385/pdf/pharmrev.122.000618.pdf
Bahena Trujillo R, Flores G, Arias Montaño JA. Dopamina: síntesis, liberación y receptores en el Sistema Nervioso Central. Rev Bioméd.2000 [citado 12/03/2024];11(1):39-60. Disponible en: https://revistabiomedica.uady.mx/index.php/revbiomed/article/view/218
Franco R, Reyes Resina I, Navarro G. Dopamine in Health and Disease: Much More Than a Neurotransmitter.Biomedicines.2021 [citado 17/03/2024];9(2):109.Disponible en:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7911410/pdf/biomedicines-09-00109.pdf
Grall Bronnec M, Victorri Vigneau C, Donnio Y, Leboucher J, Rousselet M, Thiabaud E, et al. Dopamine Agonists and Impulse Control Disorders: A Complex Association. Drug Saf. 2018 [citado 23/07/2024];41(1):19-75. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC5762774/pdf/40264_2017_Article_590.pdf
Mitchell UH, Obray JD, Hunsaker E, Garcia BT, Clarke TJ, Hope S, et al. Peripheral Dopamine in Restless Legs Syndrome. Front Neurol. 2018 [citado 23/07/2024];9:155. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC5862810/pdf/fneur-09-00155.pdf
Vlasie A, Trifu SC, Lupuleac C, Kohn B, Cristea MB. Restless legs syndrome: An overview of pathophysiology, comorbidities and therapeutic approaches (Review). Exp Ther Med.2022 [citado 17/04/2024];23(2):185. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC8764906/pdf/etm-23-02-11108.pdf
Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M. Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev. 2011 [citado 23/07/2024];2011(3):CD006009. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC8908466/pdf/CD006009.pdf
Altayb Ismail MA, Daffalla I, Singh T, Siddique QR, Almadhoun MKIK, Irfan R, et al. Efficacy of Aerobic and Stretching Exercises in Managing Willis-Ekbom Disease (Restless Leg Syndrome) Among Hemodialysis Patients. Cureus. 2024 [citado 13/03/2024];16(10):e71470. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC11563054/pdf/cureus-0016-00000071470.pdf
Cederberg KLJ, Sikes EM, Mignot E. Perceptions of exercise and restless legs syndrome: Results from a nationwide survey. J Sleep Res. 2024 [citado 11/08/2024];33(1):e13980. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC10748789/pdf/nihms-1913282.pdf
Di Stefano A, Sozio P, Cerasa LS. Antiparkinson prodrugs. Mol Basel Switz. 2008[citado 21/08/2024];13(1):46-68. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18259129
van Wamelen DJ, Grigoriou S, Chaudhuri KR, Odin P. Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson’s Disease. J Park Dis. 2018 [citado 13/03/2024];8(s1):65-72. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC6311379/pdf/jpd-8-jpd181476.pdf
Oertel W, Schulz JB. Current and experimental treatments of Parkinson disease: A guide for neuroscientists. J Neurochem. 2016 [citado 17/07/2024];139(Suppl 1):325-337. Disponible en: https://onlinelibrary.wiley.com/doi/epdf/10.1111/jnc.13750
Romagnolo A, Merola A, Artusi CA, Giorgio Rizzone M, Zibetti M, Lopiano L. Levodopa‐Induced Neuropathy: A Systematic Review – PMC. Mov Disord Clin Pract. 2018 [citado 08/09/2024]; 8;6(2):96–103. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC6384168/pdf/MDC3-6-96.pdf
Kesby JP, Eyles DW, McGrath JJ, Scott JG. Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. Transl Psychiatry. 2018 [citado 08/09/2024]; 31;8:30. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC5802623/pdf/41398_2017_Article_71.pdf
Vidal PM, Pacheco R. The Cross-Talk Between the Dopaminergic and the Immune System Involved in Schizophrenia. Front Pharmacol. 2020 [citado 13/07/2024];11:394. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC7137825/pdf/fphar-11-00394.pdf
Salvi V, Ribuoli E, Servasi M, Orsolini L, Volpe U. ADHD and Bipolar Disorder in Adulthood: Clinical and Treatment Implications. Med Kaunas Lith. 2021 [citado 21/09/2024];57(5):466. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC8151516/pdf/medicina-57-00466.pdf
Drechsler R, Brem S, Brandeis D, Grünblatt E, Berger G, Walitza S. ADHD: Current Concepts and Treatments in Children and Adolescents. Neuropediatrics. 2020[citado 17/08/2024];51(5):315-335. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC7508636/pdf/10-1055-s-0040-1701658.pdf
Purper Ouakil D, Ramoz N, Lepagnol Bestel AM, Gorwood P, Simonneau M. Neurobiology of Attention Deficit/Hyperactivity Disorder. Pediatr Res.2011 [citado 21/08/2024];69(8):69-76. Disponible en: https://www.nature.com/articles/pr9201196.pdf
Kessi M, Duan H, Xiong J, Chen B, He F, Yang L, et al. Attention-deficit/hyperactive disorder updates. Front Mol Neurosci. 2022 [citado 21/07/2024];15:925049. Disponible en: https://typeset.io/pdf/attention-deficit-hyperactive-disorder-updates-2hm65az8.pdf
MacDonald HJ, Kleppe R, Szigetvari PD, Haavik J. The dopamine hypothesis for ADHD: An evaluation of evidence accumulated from human studies and animal models. Front Psychiatry. 2024 [citado 21/03/2024];15:1492126. Disponible en: https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1492126/full
Elnaem MH, AbouKhatwa MM, Elrggal ME, Dehele IS. Attention Deficit Hyperactivity Disorder: What Are Pharmacists’ Roles and Associated Outcomes? Int J Environ Res Public Health.2023[citado 11/07/2024];20(3):2754.Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/36768120
Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry.2019 [citado 21/08/2024];24(4):562-575. Disponible en:
https://www.nature.com/articles/s41380-018-0070-0
Jangmo A, Stålhandske A, Chang Z, Chen Q, Almqvist C, Feldman I, et al. Attention-Deficit/Hyperactivity Disorder, School Performance, and Effect of Medication. J Am Acad Child Adolesc Psychiatry.2019[citado 12/10/2024];58(4):423-32. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC6541488/pdf/nihms-1025844.pdf
Published
How to Cite
Issue
Section
License
ACCESS AND DISTRIBUTION POLICY
All published articles are open access contributions, which are distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided that the primary source of publication is properly cited.
